Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.45 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.38 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.38 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.38 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.38 |
| ▸ | TET2 | Q6N021 | 3/20 | 0.37 |
| ▸ | TET3 | O43151 | 1/20 | 0.37 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5139179 | 0.85 | GABRR1 (0.72) | GABRR1CYP1A2BLMACE2LTA4H | |
| SCHEMBL20495916 | 0.80 | BLM (0.39) | GABRR1CYP1A2BLM | |
| SCHEMBL10376563 | 0.79 | CYP1A2 (0.65) | GABRR1CYP1A2BLMACE2LTA4H | |
| SCHEMBL9190094 | 0.78 | GABRR1 (0.33) | GABRR1CYP1A2 | |
| SCHEMBL297723 | 0.78 | — | — | |
| SCHEMBL9816427 | 0.77 | CYP1A2 (0.62) | GABRR1CYP1A2BLMACE2LTA4H | |
| SCHEMBL29951198 | 0.77 | CYP1A2 (0.62) | GABRR1CYP1A2BLMACE2LTA4H | |
| SCHEMBL29957798 | 0.77 | CYP1A2 (0.62) | GABRR1CYP1A2BLMACE2LTA4H | |
| SCHEMBL233225 | 0.77 | BLM (0.73) | GABRR1CYP1A2BLMACE2LTA4H | |
| SCHEMBL580558 | 0.77 | BLM (0.65) | GABRR1CYP1A2BLMACE2LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120195929-A1 | COMPOUNDS THAT MODULATE AUTOIMMUNITY AND METHODS OF USING THE SAME | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2012-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120195929-A1 | COMPOUNDS THAT MODULATE AUTOIMMUNITY AND METHODS OF USING THE SAME | HLA-DRB1, MICA, CD74 | GABRR1 1830/4885CYP1A2 3652/4885BLM 3647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.